Send to

Choose Destination
J Med Chem. 2019 Mar 14;62(5):2618-2637. doi: 10.1021/acs.jmedchem.8b01947. Epub 2019 Feb 21.

Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.

Author information

Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , U.K.
Institute for Pharmaceutical Chemistry , Johann Wolfgang Goethe-University , Max-von-Laue-Strasse 9 , D-60438 Frankfurt am Main , Germany.
Structural Genomics Consortium, BMLS , Goethe-University Frankfurt , 60438 Frankfurt , Germany.
Paediatric and Solid Tumour Biology and Therapeutics Group , The Institute of Cancer Research , 15 Cotswold Road , London SM2 5NG , U.K.
Department of Gynecology and Obstetrics , Johann Wolfgang Goethe-University , Theodor-Stern Kai 7 , 60590 Frankfurt am Main , Germany.
German Cancer Network (DKTK) , Site Frankfurt/Mainz , D-60438 Frankfurt am Main , Germany.


Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk neuroblastoma patients, mutation of ALK and amplification of MYCN. Starting from known dual polo-like kinase (PLK)-1-BRD4 inhibitor BI-2536, we employed structure-based design to redesign this series toward compounds with a dual ALK-BRD4 profile. These efforts led to compound ( R)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5 H)-one (16k) demonstrating improved ALK activity and significantly reduced PLK-1 activity, while maintaining BRD4 activity and overall kinome selectivity. We demonstrate the compounds' on-target engagement with ALK and BRD4 in cells as well as favorable broad kinase and bromodomain selectivity.

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center